The safety of live attenuated influenza vaccine in children and adolescents 2 through 17 years of age: A Vaccine Safety Datalink study.
Matthew F DaleyChristina L ClarkeJason M GlanzStanley XuSimon J HambidgeJames G DonahueJames D NordinNicola P KleinSteven J JacobsenAllison L NalewayMichael L JacksonGrace LeeJonathan DuffyEric WeintraubPublished in: Pharmacoepidemiology and drug safety (2017)
In a study of trivalent LAIV safety in a large cohort of children, few serious adverse events were detected. Anaphylaxis and syncope occurred following LAIV, although rarely. These data provide reassurance regarding continued LAIV use.